T ransfusion-related acute lung injury (TRALI) is a serious complication of blood transfusion. 1 Donor-derived antibodies against human neutrophil antigens (HNAs) and human leukocyte antigens play an important role in the pathogenesis of TRALI. 2, 3 The precise mechanism of antibody-mediated TRALI, however, is not completely understood. Activation of neutrophils by alloantibodies recognizing cognate antigens is postulated as a central mechanism. Subsequent neutrophil activation seems to trigger the release of reactive oxygen species (ROS) with inflammatory responses and sequestration of neutrophils in the lungs. 4 Some clinical studies have shown that alloantibodies against HNA-3a are implicated in cases of severe and fatal TRALI. 5 The cognate antigen, HNA-3a, was found to reside on choline transporter-like protein-2 (CTL-2), 6, 7 which is expressed on several cell types, including neutrophils and ECs. We have previously shown that anti-HNA-3a causes TRALI in mice even in the absence of neutrophils, indicating that the pulmonary endothelium itself is a major target for these alloantibodies. 8 Still, TRALI was more severe when neutrophils were not depleted from the animals. This observation suggests a role for neutrophils in anti-HNA-3a alloantibodies-mediated TRALI. However, we and others could demonstrate that anti-HNA-3a alloantibodies binding to neutrophils does not induce production of ROS. 6, 8 Apparently, a mechanism different from direct antibody-induced cellular activation must be involved.
One feature of anti-HNA-3 alloantibodies well-known to serologists is the alloantibodies' capability to induce the agglutination of neutrophils in vitro, a phenomenon which facilitates the identification of anti-HNA-3 alloantibodies in the diagnostic laboratory. 9 The mechanism underlying this phenomenon is unknown, but because this agglutination requires viable neutrophils, it is considered that neutrophil agglutination is a signaldependent, active process rather than passive cell clumping. 6 A candidate molecule for such a signaling process is CD11b/ CD18. The formation and dynamics of neutrophil aggregate formation were studied by several investigators, [10] [11] [12] and one major conclusion from these studies is that, through different chemoattractants, CD11b/CD18-dependent processes are involved in the formation of neutrophil aggregates. Whether this is true for alloantibodies -induced neutrophil aggregation has not been investigated to date. Important information on how alloantibodies against CTL-2 might affect neutrophil activation came from studies performed by Kommareddi et al. 13 Investigating the expression of CTL-2 in the inner ear, they reported an interaction between CTL-2 and cochlin. Cochlin carries 2 von Willebrand factor (VWF) A-domains, a motif identified in numerous proteins, but initially described as a major adhesion site of VWF, a central protein in hemostasis which also plays an important role in inflammation. 14 Inflammatory stimuli release ultra-large VWF from the endothelium that under shear-stress exposes the binding sites and transforms into a highly adhesive protein. Activated VWF regulates neutrophil recruitment toward endothelial surfaces and supports neutrophil extravasation. 15 Kommareddi et al's 13 observation prompted us to investigate whether CTL-2 can also interact with plasmatic VWF and whether neutrophil responses toward anti-HNA-3a alloantibodies observed in in vitro diagnostic testing and in the in vivo TRALI model are related to the presence of VWF; furthermore, we speculated that signaling via CD11b/CD18 may be involved in anti-HNA-3a alloantibodies-induced neutrophil activation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CTL-2 Specifically Binds to VWF
It was previously demonstrated that anti-CTL-2 antibodies are able to precipitate a CTL-2/cochlin complex from cochlea of the inner ear. 13 Here, we first asked the question whether recombinant CTL-2 is able to interact with immobilized cochlin. To answer this question, we generated transfected human embryonic kidney cells stably expressing CTL-2. Cell adhesion studies showed that CTL-2-transfected cells are able to bind cochlin, but not bovine serum albumin (BSA) immobilized to a mirotiter plate ( Figure 1A ). Because cochlin contains 2 VWF A-domains which could serve as binding domains for CTL-2, we repeated the experiment with transfected cells and immobilized VWF ( Figure 1B) . Indeed, cells expressing CTL-2 bound strongly to VWF, but not to controls (BSA and fibrinogen). This interaction could be specifically blocked with mab against VWF domain 1 ( Figure 1B , right), but not mab against VWF domain 3 or isotype control, indicating a specific interaction between CTL-2 and VWF. Neutrophils carry a well-characterized VWF receptor, CD11b/ CD18, 16 which we studied in parallel. Because CD11b/CD18 also binds fibrinogen, 17 all experiments were controlled with fibrinogen. As expected, human embryonic kidney cells transfected with CD11b/CD18 bound to both, VWF and fibrinogen. In direct comparison, CTL-2-transfected cells showed stronger binding to VWF than CD11b/CD18-transfected A, Adhesion of CTL-2-transfected cells to cochlin: fluorescently labeled CTL-2 (10 5 cells) and mock-transfected cells (as control) were allowed to adhere onto microtiter wells coated either with 1-μg cochlin or with bovine serum albumin (BSA) for 30 minutes at room temperature. After washings, bound cells were measured using a fluorescence microtiter reader. Data are presented as mean±SD from n=3 independent experiments; **P<0.01, n.s.=not significant. B, Adhesion of CTL-2 and CD11b/CD18-transfected cells to VWF: fluorescent labeled CTL-2, CD11b/CD18, and CTL-2/CD11b/CD18 double-transfected cells (10 5 cells) were allowed to adhere on microtiter wells coated with 1-μg VWF (100 μL of 10 μg/mL), fibrinogen or BSA. In some experiments (right columns), VWF-coated plates were blocked with 1-μg anti-VWF A1-domain (clone 724, column 1), anti-VWF A3-domain antibody (clone 82D6A3, column 2) or isotype control (column 3) before adhesion assay. Data are normalized with the absolute number of cells added to wells. Data are presented as mean±SD from n=5 independent experiments; **P<0.01, *P<0.05, n.s.=not significant.
cells. When double-transfected cells expressing CTL-2 and
CD11b/CD18 were used, they showed binding to fibrinogen and VWF as expected. However, double-transfected cells did not show an additive effect in binding to VWF when compared with cells expressing CTL-2 only; a slightly stronger binding did not reach statistical significance. Taken together, these results indicate that CTL-2 may act as specific binding partner for VWF.
VWF Is Able to Form a Trimolecular Complex With CD11b/CD18 and CTL-2 on the Cell Surface
To examine the potential role of VWF in the interaction between CTL-2 and CD11b/CD18, we tested CTL-2 and CD11b/CD18 colocalization on cell membranes in presence of VWF. For this purpose, surface labeled biotinylated cells expressing CTL-2/CD11b/CD18 were added to a plate coated with VWF, fibrinogen, or BSA. Subsequently, cells were lysed and precipitated with anti-HNA-3a alloantibodies. As shown in Figure 2A , anti-HNA-3a alloantibodies were able to pull down CD11b/CD18, when VWF was present. No specific reaction was observed with control IgG (Figure 2A , left). To prove the presence of CTL-2 in these precipitates, immunoblotting was subsequently performed with rabbit anti-CTL-2 antibody. Co-precipitation of CTL-2 was observed when CTL-2/CD11b/CD18-transfected cells were precipitated with anti-CTL-2, but not with control IgG, in particular when cells were allowed to adhere to fibrinogen and VWF. These results could be further corroborated in an antigen capture assay 18 ( Figure 2B ): double-transfected cells were added into microtiter wells coated with VWF or BSA. Subsequently, mouse monoclonal antibody (mab) against CD11b/CD18 (or isotype control) and human anti-HNA-3a alloantibodies were added. Cells were lysed and the complex comprising CD11b/CD18, CTL-2 and alloantibodies was captured by immobilized anti-mouse IgG, and detected by enzyme labeled anti-human IgG. Cells seeded on immobilized VWF showed significantly higher optical density compared with cells seeded on BSA. In the absence of VWF, no significant difference between anti-HNA-3a-treated cells and controls was observed. If no capture antibody was used, no specific signals were detected. These results demonstrate an association between CTL-2 and CD11b/CD18 in the presence of VWF, which we will refer to as trimolecular complex.
VWF Mediates Neutrophil Agglutination Induced by Anti-HNA-3a Alloantibodies
In line with our results, we sought to analyze the role of plasma VWF in neutrophil agglutination mediated by anti-HNA-3a alloantibodies ( Figure 3A ). In the presence of donor plasma, anti-HNA-3a (but not anti-HNA-3b) alloantibodies induced strong agglutination of neutrophils expressing HNA-3a (955±201 AU), whereas in a plasma-free environment (phosphate-buffered saline only, 361±65 AU) anti-HNA-3a-induced agglutination was in the range of the negative control (anti-HNA-3b IgG, 465±50 AU). A significant reduction in neutrophil agglutination was observed when the test was performed with plasma obtained from a von Willebrand factor disease type 3 patient ( Figure 3A) , indicating that VWF might be directly involved. In the next set of experiments, we analyzed whether addition of different proteins to phosphate-buffered saline would re-establish anti-HNA-3a alloantibodies-dependent neutrophil agglutination ( Figure 3B ). Indeed, strong agglutination was observed when purified VWF was supplemented before adding anti-HNA-3a alloantibodies; no such effect was observed when BSA or fibrinogen was supplemented. In line with this observation, supplementation of recombinant VWF A1-A2-A3-domains and VWF A1-domain enabled anti-HNA-3a alloantibodydependent agglutination, whereas VWF A3-domain failed to do so. Interestingly, agglutination was not observed when neutrophils were first primed with anti-HNA-3a and thereafter incubated with any of the mentioned proteins, including purified VWF. These results demonstrate that VWF A1-domain is required for neutrophil aggregate formation induced by anti-HNA-3a alloantibodies, and that VWF binding to the neutrophil is required for the initiation of this process. As to and CD11b/CD18 complex formation on transfected cells. A, Immunoprecipitation: surface biotin labeled CTL-2/CD11b/ CD18 double-transfected cells (5×10 5 ) were transferred into 6-well plates coated with bovine serum albumin (BSA), fibrinogen (Fib) or von Willebrand factor (VWF), before incubation with control IgG or anti-HNA-3a IgG. After washings adherent cells were lysed and CTL-2 complex was precipitated with protein G beads.
Immunoprecipitates were analyzed on 7.5% SDS-PAGE under reducing conditions and transferred onto polyvinylidene fluoride membranes. Membranes were then developed with peroxidaselabeled streptavidin and a chemiluminescence system (top). After stripping, membranes were redeveloped with polyclonal rabbit anti-CTL-2-NT. Bound antibodies were detected with peroxidaselabeled secondary antibodies and a chemiluminescence system (bottom). Shown are representative pictures from n=3 independent experiments. B, Antigen capture assay: CTL-2/CD11b/CD18 double-transfected cells (10 5 ) were added into microtitre wells coated with 1-μg VWF or BSA before incubation with 5 μL of 2 mg/mL anti-HNA-3a IgG and monoclonal antibody (mab) against CD11b/CD18 complex (clone Bear 1; + or mIgG; −; black columns). Cells incubated with anti-HNA-3b IgG and mab against CD11b/CD18 complex were used as controls (white columns). After washings adherent cells were lysed and transferred onto microtiter plates coated with goat anti-mouse IgG. Bound CTL-2/ CD11b/CD18 complex was then detected with peroxidaselabeled goat anti-human IgG using TMB (3,3',5,5'-tetramethylbenzidine) as substrate. Color reaction was read on an ELISA microtiter reader at 450 nm. Data are presented as mean+SD from n=3 independent experiments; *P<0.05, n.s. = not significant. HNA indicates human neutrophil antigen. be expected, no agglutination was detected in control experiments with any of the proteins when HNA-3bb-phenotyped neutrophils were used (data not shown).
We next analyzed whether anti-HNA-3a-dependent agglutination in autologous plasma could be blocked by different mabs (Figure 4 ). Similar to our findings in the adhesion assay, a mab against VWF A1-domain was able to significantly block neutrophil agglutination induced by anti-HNA-3a alloantibodies (compared with phosphatebuffered saline or isotype controls), whereas mab against VWF A3-domain was not. Inhibitory mabs against CD11b/ CD18 also reduced neutrophil agglutination. Staurosporine, an inhibitor of protein kinase C, 10 was also able to inhibit anti-HNA-3a alloantibodies-dependent neutrophil agglutination, indicating that signaling through CD11b/CD18 might be involved in anti-HNA-3a alloantibodies-induced VWF-dependent neutrophil agglutination. These observations also underline our assumption of trimolecular complex formation (alloantibody, CTL-2, and CD11b/CD18) and the hypothesis that agglutination is an active process rather than simple (passive) cell clumping.
Finally, to study the role of Fc receptors in this process, the agglutination test was performed in the presence of F(ab′) 2 and F(ab′) fragment of anti-HNA-3a alloantibodies. The monovalent Fab fragment failed to induce aggregate formation in autologous plasma (323±44 AU), whereas divalent F(ab′) 2 fragments still did ( Figure 5 ). Apparently, antigen cross-linking contributes to neutrophil agglutinate formation. However, in comparison with complete IgG (Figure 3A) , equivalent amounts of F(ab′) 2 fragments induced significantly less neutrophil aggregates (955±201 versus 627±105; P=0.04). Thus, to some degree, Fc-dependent processes seem to be involved in this observation.
Anti-HNA-3a Alloantibodies Are Able to Induce ROS Production in the Presence of VWF
To further prove functional consequences of the trimolecular complex formation involving CTL-2, CD11b/CD18, and VWF, we analyzed production of ROS in neutrophils by the use of the ferricytochrome-c assay ( Figure 6 ). Neutrophils primed with anti-HNA-3a alloantibodies are only able to produce ROS when the cells are allowed to interact with VWF.
In control experiments, neutrophils interacting with immobilized fibrinogen or BSA as well as neutrophil treated with anti-HNA-3b failed to produce ROS (data not shown). VWFdependent ROS production could be inhibited significantly by mab against VWF A1-domain, but not by mab against VWF A3-domain. In accordance with our previous results obtained in the agglutination test ( Figure 5 ), only the F(ab′) 2 fragment, but not the F(ab′) fragment of anti-HNA-3a IgG were able to induce ROS production, indicating that CTL-2 cross-linking is a prerequisite for subsequent neutrophil activation. 
Anti-HNA-3a Alloantibodies-Induced TRALI Is Mitigated in the Absence of VWF
To analyze the role of VWF in anti-HNA-3a-induced TRALI, in vivo experiments were conducted with VWF −/− mice and wild-type littermates. Purified IgG (26.7 mg/kg) derived from sera containing anti-HNA-3a alloantibodies were injected to the mice and lung water content, arterial oxygen pressure (PO 2 ), body temperature, and total leukocyte count in the bronchoalveolar lavage were measured. Similar to wild-type mice, infusion of anti-HNA-3a alloantibodies into VWF −/− miceinduced TRALI characterized by a significant increase in lung weight and decrease in arterial oxygen pressure (Figure 7) . However, lung edema in the VWF −/− mice was less severe when compared with wild-type mice (P=0.008). Furthermore, significantly less neutrophils were present in the bronchoalveolar lavage obtained from VWF knockout mice; and, more surprisingly, body temperature did not drop. These data show that the mechanism of anti-HNA-3a-mediated TRALI is at least partially dependent on VWF-mediated processes.
Discussion
In this study, we demonstrate that (1) CTL-2 can interact specifically with the A1-domain of VWF, (2) VWF, CTL-2, and CD11b/CD18 form a trimolecular complex on the neutrophil surface, (3) binding of anti-HNA-3a alloantibodies to this complex activates neutrophils, which leads to neutrophil agglutination and production of ROS, and (4) VWF-dependent mechanisms are involved in the development of anti-HNA-3a alloantibodies-dependent TRALI in mice.
The discovery of CTL-2 as target protein for anti-HNA-3a alloantibodies on the neutrophil surface has pushed forward TRALI research. 6, 7 Here, we were able to show that CTL-2 has the ability to interact with VWF, introducing VWF as a new partner in the complex molecular interplay in TRALI. VWF is an established proinflammatory mediator of leukocyte extravasation under certain experimental conditions, such as peritonitis 19 or myocardial infarction/reperfusion injury. 20, 21 After activation of the endothelium, VWF is released from Weibel-Palade bodies and can serve as a binding partner for leukocytes: either indirectly via platelet GPIb/IX complex or directly via β 2-integrins, which are known as receptors for VWF on leukocytes. 16, 22 Interestingly, we could demonstrate that our double-transfected cells (CTL-2 positive and CD11b/ CD18-positive) show efficient binding to VWF. Anti-HNA-3a alloantibodies, which bind to CTL-2, immunoprecipitated CTL-2 and CD11b/CD18 when VWF was present, supporting the hypothesis that presence of VWF (by direct or indirect way) associates CTL-2 and CD11b/CD18. Furthermore, we have also provided evidence from independent sets of experiments that in the presence of VWF, anti-HNA-3a alloantibodies induce neutrophil activation via CTL-2 and CD11b/CD18 complex. First, neutrophils agglutinate in the presence of VWF and anti-HNA-3a, a phenomenon that could be reversed by interfering with CD11b/CD18 (Figure 4 ). In addition, blockage of PKC-dependent CD11b phosphorylation 10 also interfered with neutrophils agglutination, indicating that anti-HNA-3a may transduce an outside-in signal via CD11b/CD18 leading to the formation of neutrophil agglutinates. This observation is in accordance with a previous report demonstrating that anti-HNA-3a leads to neutrophil agglutination only with viable, but not with fixed neutrophils. 6 Second, neutrophils were able to produce ROS when incubated with anti-HNA-3a alloantibodies in the presence of VWF; previously, in the absence of immobilized VWF, we and others were unable to demonstrate ROS production in neutrophils incubated with anti-HNA-3a. 6, 9 This is a relevant observation because ROS production is often considered as a central process for the rapid barrier breakdown of the pulmonary endothelium in TRALI. 23, 24 In addition, we provide evidence that activation of neutrophils by anti-HNA-3a is dependent on receptor clustering. Only F(ab′) 2 fragments, but not F(ab′) fragments of anti-HNA-3a were able to activate the cells. A previous study has shown that anti-HNA-3a-mediated neutrophil agglutination does not involve Fc receptors. 6 In our hands, purified F(ab′) 2 fragments did induce neutrophil agglutination and ROS production, but cellular responses were alleviated compared with IgG, indicating the involvement of an additional, . Superoxide production by neutrophils treated with anti-HNA-3a IgG. Washed HNA-3aa-typed neutrophils in phosphate-buffered saline (5×10 5 ) were incubated in microtiter wells coated with von Willebrand factor (VWF) and treated with 2.5-μg anti-HNA-3b IgG (Ctrl), 2.5-μg anti-HNA-3a IgG, or 200-nmol/L phorbol myristate acetate (PMA) as indicated. Inhibitory experiments were performed by treating precoated wells with monoclonal antibodies against VWF A1-or A3-domains or isotype control (Iso) before adding the cells. Reactive oxygen species production was measured by the ferricytochrome-c substrate system after 60 minutes. Data were subtracted with superoxide production of untreated cells. Data are presented as mean±SD of n=3 independent experiments; **P<0.01, *P<0.05, n.s.=not significant. HNA indicates human neutrophil antigen.
Fc-dependent mechanism. This observation is intriguing because neutrophils were found to release extracellular traps only in a CD32-dependent fashion when stimulated with anti-HNA-3a alloantibodies, 25 supporting the hypothesis that additional stimuli are required for full neutrophil activation. More recently, it was shown that DNA released from leukocytes would bind to VWF, 26 allowing for another molecular pathway that supports the inflammatory function of leukocytes. In the case of TRALI, these mechanisms would contribute further for adequate spatio-temporal availability of substances that lead to a breakdown of the endothelial barrier in the lungs.
When we induced TRALI in VWF knockout mice by the injection of anti-HNA-3a, less neutrophils were recruited to the alveolar space, less edema was present in the lungs, and the body temperature of these mice did not drop when compared with wild-type littermates. Because neutrophil activation by anti-HNA-3a alloantibodies is VWF-dependent in vitro, it is reasonable to assume that in VWF −/− mice, anti-HNA-3a alloantibodies were not able to induce neutrophil activation, release of ROS, and consequently neutrophil-mediated endothelial barrier breakdown, which would explain the reduced amount of lung water content. Our assumption that neutrophils remained inactive is supported by the fact that the body temperature did not drop; temperature control is affected by cytokines released from activated neutrophils. 8 Because VWF is involved in neutrophil transmigration, 16 it is not unexpected that the amount of neutrophils in bronchoalveolar lavage was reduced; in fact blocking VWF has been demonstrated to reduce leukocyte recruitment and vascular permeability, 19 the latter observation being an alternative explanation for reduced edema fluid in our experiments. In this respect, absence of intraalveolar neutrophil infiltration in lung tissue of anti-HNA-3a-induced fatal TRALI has been described 27 Thus, our current findings in VWF −/− mice do support our previous hypothesis that anti-HNA-3a alloantibodies-mediated TRALI is mainly driven by direct activation of ECs, whereas neutrophils (and VWF) act as facilitators in this process.
Much effort has been made to unravel the exact mechanism behind antibodies against human leukocyte antigens and TRALI. 2 To our knowledge, the fact that direct binding of human leukocyte antigen antibodies expressed on ECs can trigger the release of VWF from Weibel-Palade bodies has not been considered in detail to date. 28, 29 It is evident that the participation of VWF and CTL-2 requires further research.
In summary, our study introduces CTL-2 as a new VWFbinding partner and sheds further light on the complex mechanism of anti-HNA-3a alloantibodies-mediated TRALI. Because CTL-2 is present on ECs, platelets, and leukocytes, our observation has the potential to establish better understanding of other VWF-related processes, such as thrombosis. Figure 7 . Induction of anti-HNA-3a-mediated TRALI in von Willebrand factor (VWF) −/− mice. Lipopolysaccharide pretreated (2 mg/kg) C57BL/6J mice (wildtype and VWF −/− ) were injected with total IgG (26.7 mg/kg, n=5) isolated from serum containing anti-HNA-3a (n=3 of each group) and anti-HNA-3b (n=2 of each group) alloantibodies. Animals were euthanized 2 hours after the antibody infusion. Lung water content, arterial oxygen pressure, δ body temperature, and neutrophils count in bronchoalveolar lavage were measured. Data are presented as mean±SD with ***P<0.001, **P<0.01, *P<0.05, n.s.=not significant. HNA indicates human neutrophil antigen.
